Asset Planning,Inc Esperion Therapeutics, Inc. Transaction History
Asset Planning,Inc
- $138 Billion
- Q3 2025
A detailed history of Asset Planning,Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Asset Planning,Inc holds 900 shares of ESPR stock, worth $2,556. This represents 0.0% of its overall portfolio holdings.
Number of Shares
900
Previous 900
-0.0%
Holding current value
$2,556
Previous $886,000
169.19%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ESPR
# of Institutions
184Shares Held
106MCall Options Held
139KPut Options Held
604K-
Black Rock Inc. New York, NY14MShares$39.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$33.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.3MShares$29.4 Million0.05% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$28.3 Million0.18% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$19 Million4.26% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $189M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...